Study Comparing IMC-F106C and Nivolumab Treatments in Patients with Advanced Melanoma

Inclusion Criteria

• Must have a specific genetic marker called HLA-A*02:01.
• Must have been diagnosed with advanced melanoma that is either Stage IV or cannot be surgically removed at Stage III.
• Must provide a tumor sample that is suitable for testing.
• Must have measurable cancer according to standard criteria.
• Must have the BRAF V600 mutation status checked.
• Must be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• If of childbearing potential and sexually active, must agree to use effective birth control during the study and for 5 months after the last treatment.

Exclusion Criteria

• Have a history of other cancers not being treated in this study.
• Have untreated or active cancer spread to the brain or spinal cord.
• Have allergies to the study drugs or their ingredients.
• Have significant lung or heart disease.
• Have an active autoimmune disease requiring treatment that suppresses the immune system.
• Have any poorly controlled medical condition that could affect participation in the study.
• Have received previous treatment for melanoma that cannot be removed or has spread.
• Have had a severe reaction to previous treatments targeting PD-(L)1 or LAG-3.